Physician profile
John B Fileta
NPI 1013237676
$1,688.78
in general payments reported to CMS, 2019-2025
19 companies · $374 in 2025
The $374 reported for 2025 was less than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $110 · 2021: $204 · 2022: $266 · 2023: $254 · 2024: $371 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $407.44 | 2019-2025 | Argos, Clareon Panoptix Pro, Clareon |
| Dompe US, INC. | $160.44 | 2022-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $157.85 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Abbvie INC. | $137.10 | 2022-2025 | |
| Biotissue Holdings INC. | $122.44 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $110.33 | 2019-2025 | Cequa |
| Allergan, INC. | $110.11 | 2020-2022 | |
| Oyster Point Pharma, INC. | $91.74 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $72.95 | 2024 | Xdemvy |
| Ocular Therapeutix, INC. | $66.23 | 2021-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $49.01 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $42.48 | 2023-2024 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Aerie Pharmaceuticals, INC. | $36.91 | 2019-2020 | |
| Omeros Corporation | $32.00 | 2021 | |
| Harrow Eye, LLC | $25.30 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $20.98 | 2025 | Photrexa Viscous and Photrexa |
| Kala Pharmaceuticals, INC. | $18.55 | 2021 | |
| Eyevance Pharmaceuticals LLC | $15.16 | 2020 | |
| Celularity INC. | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fileta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.